What Investors Look for in Life Sciences Insurance Diligence

Insurance is a routine line item in venture and strategic diligence packages, and a substantive one for life sciences companies. Lead investor counsel will ask for in-force coverage summaries, sample certificates of insurance, and policy declarations. The reading takes minutes for a straightforward technology company. For a life sciences company, the reading is longer and the gap-finding more substantive, because the regulatory exposure surface is wider and the structural decisions in the program are more consequential.

This is a two-sided guide. Founders preparing for diligence need to understand what investors actually look for, where the common gaps surface, and how to structure the conversation. Investors evaluating a life sciences portfolio company need to understand what an adequate program looks like at the target’s stage and segment, what the red flags are, and how insurance gaps should affect the valuation or terms conversation.

What Counsel Actually Checks

Lead investor counsel works through a short, mechanical list when reviewing an insurance program.

Is coverage in place and current. Effective dates, expiration dates, premium payment status. A policy that lapsed three months ago is a problem regardless of what it says.

Are limits commensurate with the round. Counsel has internal benchmarks for what a Series A or Series B life sciences company typically carries by segment. A program that sits materially below those benchmarks gets flagged.

Is the named insured correct. The policy needs to cover the operating entity that is taking the investment, not a legacy holding company or a pre-formation entity name.

Does D&O include Side A. This is non-negotiable when an institutional director is joining the board.

Does cyber include regulatory defense and breach response. For HIPAA-regulated targets, generic cyber that caps regulatory limits below current enforcement levels is a flag.

Does products liability address the actual exposure. For medical device and SaMD targets, the policy needs to be a real life sciences placement, not a generic technology product liability extension.

Does Tech E&O contemplate the company’s actual offering. For SaMD and clinical decision support, generic tech E&O that does not address clinical decision impact creates a gap. For the substantive structural framing on SaMD specifically, see What insurance does an FDA-regulated SaMD company need?.

Are effective dates aligned to the close. Coverage effective the day before close is fine; coverage effective the day after close is a problem.

Stage-Calibrated Expectations

Investor expectations are calibrated to stage. The same gap can be a deal-stopper at Series B and a minor item at seed.

Pre-seed and seed. Light expectations. Basic management liability, general liability, workers’ compensation. The diligence question is whether the company has thought about it, not whether the program is fully mature.

Series A. Substantive expectations. D&O with Side A, cyber if the company touches data, products liability if there is a regulated product. The lead investor’s counsel will ask for the coverage summary and read it. For the segment-specific Series A framing, see What insurance does a digital health startup need to raise a Series A?.

Series B. Mature expectations. Structured D&O tower, dedicated EPLI, segment-appropriate products and Tech E&O, mature cyber, evidence of program restructuring from Series A.

Growth and pre-exit. Public-company-ready expectations. Multi-layer D&O tower, dedicated Side A, full management liability suite, comprehensive cyber, and a clean claims history with no significant open matters.

Common Red Flags

Several patterns surface repeatedly in life sciences diligence and produce investor concern.

No D&O at all when raising institutional capital. This is the most basic gap. The lead investor cannot place a director on the board without Side A protection in force.

Stale or missing BAAs. OCR’s Risk Analysis Initiative has elevated business associate scrutiny. A digital health or clinical lab target with an incomplete BAA inventory creates a regulatory and insurance gap that the investor will not absorb.

Generic technology cyber for HIPAA-regulated operations. A cyber policy that caps regulatory defense or excludes PHI-related contractual liability does not address the actual exposure of a HIPAA-regulated company.

No products liability for a medical device company. Some pre-clearance device companies operate without products liability because the product has not yet been distributed. As soon as the company is in clinical trials or post-clearance, the gap becomes a deal item.

Generic startup bundled programs. Programs sold to general technology startups frequently exclude PHI, exclude FDA-regulated products, or cap key limits below what a regulated-sector company needs.

No claims history disclosure or evasive responses. Counsel reads loss runs. A target that cannot produce loss runs, or whose responses are inconsistent, raises diligence concerns beyond the specific claim history.

Lapsed policies or unpaid premiums. A program with administrative gaps suggests broader operational discipline issues.

Effective dates misaligned with corporate events. A policy that started before incorporation, ended before the close, or has a structural date issue is a flag for how the company handles compliance generally.

How Insurance Affects Valuation and Terms

Insurance gaps surface in two ways during a transaction. The first is as a closing condition. The investor or acquirer requires specific coverage to be in place before close, which means the company is placing the program under deadline pressure. This typically produces worse terms than a deliberate pre-diligence placement.

The second is as a price or term consideration. A material gap in D&O, products liability, or cyber can adjust the term sheet through an indemnification carve-out, an escrow allocation, or a holdback. The amount is rarely dollar-for-dollar with the gap, but the gap influences how the indemnification structure is negotiated.

For acquirers, insurance gaps in the target also affect the integration plan. Tail coverage decisions, run-off considerations, and the alignment of the target’s program with the acquirer’s are all real items that show up in the acquisition agreement and the operational integration timeline.

How Founders Should Prepare

The cleanest preparation starts 60 to 120 days before the diligence package is requested.

Build the coverage summary document. A single PDF or working document with policy summaries, effective dates, limits, retentions, named insured, and key endorsements. Investor counsel can read this in five minutes if it is well-structured, in an hour if it is not.

Inventory and refresh BAAs where applicable. For digital health and clinical lab companies, an up-to-date BAA register is a meaningful diligence asset.

Pull loss runs from each carrier. Standard request. Have them ready.

Confirm the named insured matches the operating entity. This is the most common mechanical issue.

Identify any open claims or known incidents. Disclose them in the diligence package rather than letting them surface as questions.

Identify structural gaps before the investor does. A gap that the founder identifies and is working to remediate reads differently from a gap the investor finds.

The Diligence Conversation Sequence

The insurance diligence typically runs through a predictable sequence, and founders who understand the sequence can position the program more effectively.

The data request. Investor counsel sends a standard insurance request as part of the broader diligence list. The request typically asks for the coverage summary, sample certificates, loss runs, and a statement of the named insured for each policy. Founders who have prepared the materials in advance respond quickly; founders who scramble produce inconsistent responses that prompt follow-up questions.

The first review. Counsel reads the materials, identifies any obvious gaps, and flags structural concerns. The most common first-review flags are missing Side A, incorrect named insured, lapsed policies, and inadequate cyber for HIPAA-regulated operations.

The follow-up questions. Counsel returns with specific questions: about claims history, about regulatory engagement, about specific policy provisions, and about the gap items flagged in first review. The depth and specificity of these questions is a signal of how the diligence is going.

The structural conversation. If the gaps are substantive, counsel and the company’s broker work toward a remediation plan. This may include placing new coverage, restructuring existing coverage, or documenting why a perceived gap is not actually a gap. The structural conversation is where preparation pays off.

The closing condition. The investor may require specific coverage to be in place as a closing condition. The condition is specific: it names the coverage line, the limit, and sometimes the effective date. Founders meeting closing conditions under deadline pressure typically secure worse terms than founders who anticipated the requirement.

Acquirer-Specific Considerations

When the transaction is an acquisition rather than a financing, the insurance diligence has additional dimensions.

Tail coverage for the target. Run-off coverage protecting the target’s directors and officers for pre-closing acts becomes the central D&O conversation. A six-year tail is standard; the specific terms, exclusions, and acceptable carriers are negotiated as part of the transaction.

Acquirer’s program integration. The acquirer’s existing insurance program needs to incorporate the target’s operations. This may require endorsements, new placements for previously uncovered exposures (FDA-regulated products, HIPAA-regulated data, CLIA-certified operations), and a transition plan for the target’s standalone policies.

Pre-closing claim review. Counsel reviews any open claims, known incidents, and regulatory matters affecting the target. These can become indemnification items, escrow items, or holdback items.

Representations and warranties insurance. R&W insurance has become increasingly common in life sciences M&A. The R&W policy intersects with the underlying insurance program in specific ways that need explicit attention.

How Investors Should Evaluate

Investors evaluating a life sciences target should approach insurance as a substantive diligence area rather than a checklist item.

Calibrate expectations to stage and segment. A pre-clearance medical device company does not need a commercial-launch products program. A pre-revenue digital health company does not need enterprise-scale cyber. Misaligned benchmarks produce false flags.

Read the wording, not just the limit. A high limit with a substantive exclusion is worse than a moderate limit with a clean wording. Coverage triggers, definitions, and exclusions matter.

Probe regulatory history. FDA correspondence, OCR communications, state attorney general inquiries, and CLIA inspection findings all interact with the insurance program. The target’s regulatory history is part of the insurance diligence.

Look at program structure, not just policy presence. A D&O policy in place that lacks Side A is a different thing from a D&O policy in place with proper Side A separation. The structural choices matter as much as the coverage existence.

Coordinate with management liability counsel. For Series B and later, the D&O analysis benefits from counsel who specializes in management liability. The structural choices at this stage have material consequences over the long term.

A Note on Placement

MedTech Coverage works with life sciences founders preparing for diligence and with funds evaluating portfolio companies. Coverage is placed and reviewed through Tower Street Insurance’s appointments with specialty life sciences markets, with structural attention to the stage-calibrated expectations investor counsel applies.

If a diligence process is approaching or an existing program needs a structural review before a round opens, a coverage review produces a working document mapped to what investor counsel actually checks and where the typical gaps surface.